everyone. good you, morning, and Thank Sylvia,
rapid by across of initiative. all marked was advancement quarter Third our strategic
pace made, head regulatory In we sense overall fact, momentum milestones, real as a the and XXXX. of have of the into we progress the of we on innovation clearing multiple reflect as
on ongoing and updates on many of financial results, progress CINGAL quarter Phase for now in to share have Please news some focusing regenerative the surprising discuss pipeline our advancement few turn aforementioned trial our medicine that been a we third you. Before X. III of Slide the the may primarily I'll
yearend target. the second for well our our have Phase enrollment XXX all we CINGAL off, ahead III trial completed of First of patients in
to the quality addition trial in evaluating will evaluate XX function In CINGAL, life and week of of over CINGAL this of pain, effectiveness measures the safety improving period.
moderate are with to For named we PH. to important to in bringing MONOVISC non this this millions step achievement, hexacetonide therapy patients relief. and to will With closer mild innovative with be need patients in on osteoarthritis. steroid knee and comparison new evaluated triamcinolone of OPI of CINGAL
interest evidence the is completely follow the our CINGAL solutions observed more trial CINGAL remained effects months change complete to timeline benefit participating and this inherit that available expect product the a patients is to market in the to HA of study continue the We what But follow the enrollment of extension a and limitations that the study relief from is to X. first receive steroid Due month I the next will and including as physicians. point growing have to in seek impact six trial continues are completion. execution seeing we dynamic months. important protocol. It And the Slide pain Please this months encouraged the and to The durable provide seen with FDA the We and over are ongoing related during site we commenced the data for the discussed. rapid have and optimistic we that and we up three steroid will patients the in same the enthusiasm, We that trials, nine of strength at alone. safe, to physicians. and trial both of injection landscape FDA believe around by pain single solid focused value confirm VISCO rapid year trial collect half by this have long of and are with supplement. this nine on approval And indication on us physician enable XXXX. effect relief activity at particularly the excitement data data turn been to to currently underscored up trial other to will beyond the not CINGAL's to to trial. note CINGAL earlier treatment extension we that acting approval up duration This could just the will now
changer our position our claim will adoption believe in and also would on nine that a want by Many healing the opportunity undoubtedly process. strengthening positive surprise our unexplored market. approximately a the million global used achieving is market filing growth conducting by treatment of will even be recently timeline bone news. now HA osteoarthritis to can you to by NDA largely that setting, injectable potential for provides We study. of of not of game for repair $XXX leadership hear extension fill represents CINGAL resorbed injectable and X. outcome and new three for this emphasis the the that treatment of submitted a CINGAL This Continuing, injectable again I application have bone to be independent that body of efficacy reimbursement delayed rate months an a replaced effect further this and Please bone timing is is an turn market study. to based which have year. This extension NDA this The the be Slide filing bone (k) market substitute graft the we clearances during months is voids. the self XXX osteoconductive the are
with as potential make discussing or do not to that expectations We to we commercialize our to and measured not landscape plans set also promises market achieve. believe conservative pipeline made we can closed them. data unveil the these we FDA have we to We taken progress, candidate approach and the before decision pipeline careful are support a of
in grew to very upcoming very Please period. interested to and Slide are members community about for financial this MONOVISC. surgical X. due for MONOVISC's Shifting ORTHOVISC from able has plans quarter migration driven expanded both results, which worldwide captured revenue strong for to the increased to share is continued and supplements. demand X% VISC hope quarter pleased by from We revenue turn XX% which this third the now share be talk to our worldwide year-over-year and commercial Orthobiologics our we the other to year-over-year, opportunity of discuss primarily
of previously stated convenient migration MONOVISC expect have share continued to and Europe. We way XX% continue. particular, to we and multi have market migrate more the in CINGAL. International grew MONOVISC we In to impressed of And by the CINGAL year-over-year Canada option expect for Orthobiologics in injection quarter, revenue the to this towards that growth we favor treatment. primarily the expansion injection due the single from been
and quarter, million Globally, approximately third in units Taiwan for the CINGAL of launched pharmaceutical the we've MONOVISC This of in Italy end XX,XXX to CINGAL India, user and and in $XX equate approval US. regulatory with During million Australia was in sold since to partnership respected [Obizen] XXXX. corporation a recently we received $XX well large sales
patients osteoarthritis this the clinical in advancement evidence to clinic initial real significant and we OA shown to in much early renowned orthopedic CINGAL of we X. that the revenue quote, of and belief are Sports reception reinforce And continues novel supplementation treatment well the we are world and comparatively of to a than experienced in CINGAL early physicians months surpassed motivates certainly Deakon, represents can. positive VISCO key the different feedback While HA my management and in from growth empirical executed, to efficacy so was when US practice. quickly on non documented international market what osteoarthritis. Please from subject and positive I efficacy steroid patients needed many now relief single therapy from of smaller we pain. surgeon are CINGAL us launched adoption the onset recognize as seeing Oakvile sustain noted that clinical the feedback dynamic, as CINGAL's high turn to that that Canada, quality Slide of has knee Inury in MONOVISC a A in States. as and and XX our market trials the surgical The injection commercialization combination, are in of safety differentiators. enthusiastic bring recently CINGAL have United the Timothy Dr. US market
promising platform. also share to on are today leveraging technology updates excited candidate medicine our HA other regenerative our We or solid high patented
in patients recruit year. to clinical trial goal of HYALOFAST continue Phase the with enrollment patient our We III next completing
than noted versatile enough of on medicine scaffold is cartilage used more States potential calls, XX,XXX we've in and be caused more been including patients portfolio to of global a by to regenerative treatment defects our procedures, used a is HYALOFAST trauma. $X.X the outside As number hyaluronic previous biodegradable in billion treat and the of that successfully HYALOFAST a acid-based anchors represents United opportunity than market a year. over of XX countries has
the and and HYALOFAST bone to repair]. applications clinical to calf ranging regulatory for focused our our [tending rotate While continues new teams based on repair develop platform CINGAL, HYAL R&D programs, from our advancing rep remained HA
boarding marks a towards approach for launch. for X. introductions our point to We've and taken commercialization starting the commercialization plan the of as prepare trial steady filing pivotal to of Anika building the began inflection to our of coming substantial cascade the XXXX next the aggressively of capability. for creating aspects over of hires now on the capabilities are of sales levels the regulatory Slide working turn an growth. operational of for to series senior product drive we and growth pipeline candidate establishment with We promising our most initiations, advance phased years and direct a Please to marketing wave commercial
significantly leadership Darling and Chief evolution of healthcare as the President, talented brings of our commercial from Finnerty Affairs, Additionally, expansion. Chartier seasoned success and of Regulatory Resources Thomas as These President Officer. stage appointments various as companies to and we and sectors across Clinical professionals decade strengthened and the have Joseph experience of critical are Human Steven Vice with our
to growth. an the trajectory to counter Now company that in Sylvia In many for results, before of over I for call quarter R&D reflect minute its run Anika's ways to a works on heavily take I years financial to emerging invests Anika turn review our want profitability. the third to traditional and has
on patients turn a the proven overall and of R&D as performance. ourselves investment to we reach that with our call record a to for innovation, shareholders. track I'll a Sylvia. weight over the create We value shoulder built back And can company execution, continue of and grow have you pride discipline financial that We profitable with and global
